{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002021232,0.002557346,0.005699834,0.0005523631,0.0004880276,0.001678903,0.001400876,0.003170215,0.007954195],"category_scores_gemma":[0.002475582,0.0009701212,0.004581523,0.0004957592,0.001649494,0.002214848,0.0005165339,0.004764134,0.001521911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001114053,"about_ca_system_score_gemma":0.001117883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001262787,"about_ca_topic_score_gemma":0.002909564,"domain_scores_codex":[0.9989942,0.0005000847,0.00006712015,0.000202333,0.00006572564,0.0001705098],"domain_scores_gemma":[0.9990222,0.0003273113,0.0001981005,0.00007016165,0.00007132019,0.0003109092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9862153,0.001657608,0.0002581927,0.0008598177,0.00129472,0.00003139125,0.000035167,0.0002842268,0.000832273,0.00008889875,0.0007185132,0.007723949],"study_design_scores_gemma":[0.976469,0.02175563,0.0004557736,0.00002785865,0.0004760611,0.00002749625,0.00001652364,0.0002559519,0.00009660816,0.000110761,0.0002953969,0.00001291374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9680918,0.01771316,0.001035291,0.001978092,0.002107888,0.003588949,0.001848806,0.0003064121,0.00332953],"genre_scores_gemma":[0.9838048,0.005275236,0.001317965,0.00141851,0.0007005581,0.002538042,0.001333908,0.0000378046,0.003573262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007954195,"threshold_uncertainty_score":0.02660948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04042620639566981,"score_gpt":0.4065506950648967,"score_spread":0.3661244886692269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}